Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study

Affiliations

• ¹ Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Filipa_Lynce@dfci.harvard.edu.
• ² Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA. Filipa_Lynce@dfci.harvard.edu.
• ³ Harvard Medical School, Boston, MA, USA. Filipa_Lynce@dfci.harvard.edu.
• ⁴ MedStar Georgetown University Hospital, Washington, DC, USA.
• ⁵ Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
• ⁶ Georgetown University, Washington, DC, USA.
• ⁷ NeoGenomics, Durham, NC, USA.
• ⁸ MedStar Washington Hospital Center, Washington, DC, USA.
• ⁹ Tufts Medical Center, Boston, MA, USA.
• ¹⁰ University of Chicago, Chicago, IL, USA.
• ¹¹ Hackensack University Medical Center, Hackensack, NJ, USA.
• ¹² University of Alabama at Birmingham, Birmingham, AL, USA.
• ¹³ AstraZeneca, Arlington, VA, USA.
• ¹⁴ Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD, USA.
• ¹⁵ Inova, Fairfax, VA, USA.
• ¹⁶ The Ohio State University, Columbus, OH, USA.
• ¹⁷ Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
• ¹⁸ Harvard Medical School, Boston, MA, USA.
• ¹⁹ Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.